Analysts Set Humana Inc. (NYSE:HUM) PT at $288.60

Humana Inc. (NYSE:HUM) has been assigned a consensus rating of “Hold” from the twenty-three ratings firms that are covering the company, Marketbeat.com reports. Seventeen investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $284.90.

HUM has been the topic of a number of research reports. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Barclays boosted their price objective on shares of Humana from $270.00 to $322.00 and gave the stock an “equal weight” rating in a report on Friday, April 11th. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th.

Institutional Trading of Humana

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares in the last quarter. Dodge & Cox boosted its holdings in Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares in the last quarter. Pzena Investment Management LLC grew its stake in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after acquiring an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after acquiring an additional 63,562 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Humana by 29.8% in the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock worth $608,348,000 after purchasing an additional 550,692 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $246.07 on Tuesday. The firm has a market capitalization of $29.70 billion, a P/E ratio of 24.73, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock’s 50-day simple moving average is $265.62 and its two-hundred day simple moving average is $270.27. Humana has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts anticipate that Humana will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.44%. Humana’s payout ratio is 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.